Eli Lilly and (LLY)

Although the stock has experienced its fair share of turbulence in 2025, Eli Lilly LLY is rapidly emerging as a key consideration for investors seeking to hedge their portfolios away from tech and AI ...

Eli Lilly and Company's orforglipron shows strong efficacy and manufacturing advantages over Novo Nordisk's oral semaglutide, supporting future growth in the obesity and diabetes market. Orforglipron'...

In 2018, Apple became the first publicly traded company to reach a $1 trillion market capitalization. Several more have joined that club since, but it remains highly exclusive, with fewer than 10 memb...

According to a filing with the Securities and Exchange Commission dated Aug. 12, 2025, Stevens Capital Management LP completely exited its position in Eli Lilly and Company (LLY -0.20%), by selling al...

Eli Lilly and Co (NYSE:LLY) has halted shipments of its Mounjaro diabetes and weight-loss drug to the UK ahead of a planned price hike next month. Earlier this week the US drug giant warned against "i...

Eli Lilly has temporarily paused shipments of its weight-loss drug Mounjaro in the UK, ahead of a new price hike for the treatment set to come into effect starting next month.

Key Points in This Article: Eli Lilly's (LLY) Zepbound has outshone Novo Nordisk's Wegovy, achieving superior weight-loss results in clinical trials.

Major U.S. equities indexes ticked higher as investors looked past concerns about President Donald Trump's effort to remove Federal Reserve Governor Lisa Cook and ahead to Wednesday's Nvidia earnings ...

There's nothing like a successful clinical trial of a high-potential medicine to blast a pharmaceutical company's stock price higher. That was the dynamic behind Eli Lilly's (LLY 5.67%) nearly 6% gain...